## **ForPatients**

## by Roche

Squamous Cell Carcinoma Advanced Solid Tumors Non-Small Cell Lung Cancer (NSCLC) Triple Negative Breast Cancer Colorectal Cancer (CRC) Gastric Cancer Non Small Cell Lung Carcinoma Urothelial Carcinoma Squamous Cell Carcinoma of the Head and Neck (SCCHN) Esophageal Cancer Hepatocellular Carcinoma (HCC) Metastatic Solid Tumors Malignant Melanoma Clear Cell Renal Cell Carcinoma Melanoma Cervical Cancer

## A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7502175 as a Single Agent and in Combination With Checkpoint Inhibitor in Participants With Locally Advanced or Metastatic Solid Tumors

Trial Status Trial Runs In Trial Identifier
Recruiting 7 Countries NCT05581004 2021-006708-34
GO43860

The source of the below information is the publicly available website ClinicalTrials.gov. It has been summarised and edited into simpler language.

## Trial Summary:

This is a first-in-human study to evaluate the safety, tolerability, pharmacokinetics (PK), and anti-tumor activity of RO7502175 when administered as a single agent and in combination with atezolizumab or pembrolizumab in adult participants with locally advanced or metastatic solid tumors, including non-small-cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), melanoma, triple-negative breast cancer (TNBC), esophageal cancer, gastric cancer, cervical cancer, colorectal cancer (CRC), urothelial carcinoma (UC), clear cell renal cell carcinoma (RCC) and hepatocellular carcinoma (HCC). Participants will be enrolled in 2 stages: dose escalation and dose expansion.

Genentech, Inc. Sponsor		Phase 1 Phase	
NCT05581004 2021-006708-34 GO43860 Trial Identifiers			
Eligibility Criteria:			
Gender All	Age >=18 Years	Healthy Volunteers No	